Advertisement

Remission of Crohn's disease on bupropion

  • Richard E. Kast
    Affiliations
    Department of Psychiatry, College of Medicine, University of Vermont, Burlington, Vermont, Brain and Perception Laboratory, University of California, San Diego, La Jolla, California
    Search for articles by this author
  • Eric Lewin Altschuler
    Affiliations
    Department of Psychiatry, College of Medicine, University of Vermont, Burlington, Vermont, Brain and Perception Laboratory, University of California, San Diego, La Jolla, California
    Search for articles by this author

      Abstract

      GASTROENTEROLOGY 2001;121:1260-1261
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sartor RB
        New therapeutic approaches to Crohn;s disease.
        N Engl J Med. 2000; 342: 1664-1666
        • Papadakis KA
        • Targan SR
        Role of cytokines in the pathogenesis of inflammatory bowel disease.
        Annu Rev Med. 2000; 51: 289-298
        • Present DH
        • Rutgeerts P
        • Targan S
        • Hanauer SB
        • Mayer L
        • van Hogezand RA
        • Podolsky DK
        • Sands BE
        • Braakman T
        • De Woody KL
        • Schaible TF
        • van Deventer SJ
        Infliximab for the treatment of fistulas in patients with Crohn's disease.
        N Engl J Med. 1999; 340: 1398-1405
        • Best WR
        • Becktel JM
        • Singleton JW
        Rederived values of the eight co-efficients of the Crohn's Disease Activity Index (CDAI).
        Gastroenterology. 1979; 77: 843-846
        • Talmadge J
        • Scott R
        • Castelli P
        • Newman-Tarr T
        • Lee J
        Molecular pharmacology of the β-adrenergic receptor on THP-1 cells.
        Int J Immunopharmacol. 1993; 15: 219-228
        • Prabhakar U
        • Lipshutz D
        • Bartus JO
        • Slivjak MJ
        • Smith 3rd, EF
        • Lee JC
        • Esser KM
        Characterization of cAMP dependent inhibition of LPS induced TNF production by rolipram, a specific phosphodiesterase IV inhibitor.
        Int J Immunopharmacol. 1994; 16: 805-816
        • Guirao X
        • Kumar A
        • Katz J
        • Smith M
        • Lin E
        • Keogh C
        • Calvano SE
        • Lowry SF
        Catecholamines increase monocyte TNF receptors and inhibit TNF through β-2 adrenoreceptor activation.
        Am J Physiol. 1997; 273: E1203-E1208
        • Sommer N
        • Loschmann PA
        • Northoff GH
        • et al.
        The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalitis.
        Nat Med. 1995; 1: 244-248
        • Goebel MU
        • Mills PJ
        • Irwin MR
        • Ziegler MG
        Interleukin-6 and tumor necrosis factor-alpha production after acute psychological stress, exercise, and infused isoproterenol: differential effects and pathways.
        Psychosom Med. 2000; 62: 591-598
        • Kast RE
        Crohn's disease remission with phenelzine.
        Gastroenterology. 1998; 115: 1034-1035
        • Magro F
        • Vieira-Coelho MA
        • Fraga S
        • Serrao MP
        • Tavarela-Veloso F
        • Tome-Ribeiro
        • Soares-da-Silva P
        Impaired synthesis or cellular storage of norepinephrine, dopamine and 5-hydroxytryptamine in inflammatory bowel disease (abstr).
        Am J Gastroenterol. 2000; 95: 2556
        • Leib J
        Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors.
        Int J Immunopharmacol. 1983; 5: 353-357
        • Altschuler EL
        Monoamine oxidase inhibitors in rheumatoid arthritis- anti-tumor necrosis factor?.
        Int J Immunopharmacol. 2000; 22: 1007-1008
        • Sanchez C
        • Hyttel J
        Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
        Cell Mol Neurobiol. 1999; 19: 467-489
        • Garrrcha G
        • Smokcum RW
        • Stephenson JD
        • et al.
        Effect of some atypical antidepressants on β-adrenoreceptor binding and adenylate cyclase activity in the rat forebrain.
        Eur J Pharmacol. 1985; 108: 1-7